Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses
Abstract Cognitive impairment (CI) is common in α-synucleinopathies, i.e., Parkinson’s disease, Lewy bodies dementia, and multiple system atrophy. We summarize data from systematic reviews/meta-analyses on neuroimaging, neurophysiology, biofluid and genetic diagnostic/prognostic biomarkers of CI in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-024-00823-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850180413179297792 |
|---|---|
| author | Elisa Mantovani Alice Martini Alessandro Dinoto Chiara Zucchella Sergio Ferrari Sara Mariotto Michele Tinazzi Stefano Tamburin |
| author_facet | Elisa Mantovani Alice Martini Alessandro Dinoto Chiara Zucchella Sergio Ferrari Sara Mariotto Michele Tinazzi Stefano Tamburin |
| author_sort | Elisa Mantovani |
| collection | DOAJ |
| description | Abstract Cognitive impairment (CI) is common in α-synucleinopathies, i.e., Parkinson’s disease, Lewy bodies dementia, and multiple system atrophy. We summarize data from systematic reviews/meta-analyses on neuroimaging, neurophysiology, biofluid and genetic diagnostic/prognostic biomarkers of CI in α-synucleinopathies. Diagnostic biomarkers include atrophy/functional neuroimaging brain changes, abnormal cortical amyloid and tau deposition, and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers, cortical rhythm slowing, reduced cortical cholinergic and glutamatergic and increased cortical GABAergic activity, delayed P300 latency, increased plasma homocysteine and cystatin C and decreased vitamin B12 and folate, increased CSF/serum albumin quotient, and serum neurofilament light chain. Prognostic biomarkers include brain regional atrophy, cortical rhythm slowing, CSF amyloid biomarkers, Val66Met polymorphism, and apolipoprotein-E ε2 and ε4 alleles. Some AD/amyloid/tau biomarkers may diagnose/predict CI in α-synucleinopathies, but single, validated diagnostic/prognostic biomarkers lack. Future studies should include large consortia, biobanks, multi-omics approach, artificial intelligence, and machine learning to better reflect the complexity of CI in α-synucleinopathies. |
| format | Article |
| id | doaj-art-cd676f4f4df7403e9d88af2199fdb13e |
| institution | OA Journals |
| issn | 2373-8057 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj-art-cd676f4f4df7403e9d88af2199fdb13e2025-08-20T02:18:10ZengNature Portfolionpj Parkinson's Disease2373-80572024-11-0110111710.1038/s41531-024-00823-xBiomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analysesElisa Mantovani0Alice Martini1Alessandro Dinoto2Chiara Zucchella3Sergio Ferrari4Sara Mariotto5Michele Tinazzi6Stefano Tamburin7Department of Neurosciences, Biomedicine and Movement Sciences, University of VeronaSchool of Psychology, Keele UniversityDepartment of Neurosciences, Biomedicine and Movement Sciences, University of VeronaSection of Neurology, Department of Neurosciences, Verona University HospitalSection of Neurology, Department of Neurosciences, Verona University HospitalDepartment of Neurosciences, Biomedicine and Movement Sciences, University of VeronaDepartment of Neurosciences, Biomedicine and Movement Sciences, University of VeronaDepartment of Neurosciences, Biomedicine and Movement Sciences, University of VeronaAbstract Cognitive impairment (CI) is common in α-synucleinopathies, i.e., Parkinson’s disease, Lewy bodies dementia, and multiple system atrophy. We summarize data from systematic reviews/meta-analyses on neuroimaging, neurophysiology, biofluid and genetic diagnostic/prognostic biomarkers of CI in α-synucleinopathies. Diagnostic biomarkers include atrophy/functional neuroimaging brain changes, abnormal cortical amyloid and tau deposition, and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers, cortical rhythm slowing, reduced cortical cholinergic and glutamatergic and increased cortical GABAergic activity, delayed P300 latency, increased plasma homocysteine and cystatin C and decreased vitamin B12 and folate, increased CSF/serum albumin quotient, and serum neurofilament light chain. Prognostic biomarkers include brain regional atrophy, cortical rhythm slowing, CSF amyloid biomarkers, Val66Met polymorphism, and apolipoprotein-E ε2 and ε4 alleles. Some AD/amyloid/tau biomarkers may diagnose/predict CI in α-synucleinopathies, but single, validated diagnostic/prognostic biomarkers lack. Future studies should include large consortia, biobanks, multi-omics approach, artificial intelligence, and machine learning to better reflect the complexity of CI in α-synucleinopathies.https://doi.org/10.1038/s41531-024-00823-x |
| spellingShingle | Elisa Mantovani Alice Martini Alessandro Dinoto Chiara Zucchella Sergio Ferrari Sara Mariotto Michele Tinazzi Stefano Tamburin Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses npj Parkinson's Disease |
| title | Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses |
| title_full | Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses |
| title_fullStr | Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses |
| title_full_unstemmed | Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses |
| title_short | Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses |
| title_sort | biomarkers for cognitive impairment in alpha synucleinopathies an overview of systematic reviews and meta analyses |
| url | https://doi.org/10.1038/s41531-024-00823-x |
| work_keys_str_mv | AT elisamantovani biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT alicemartini biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT alessandrodinoto biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT chiarazucchella biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT sergioferrari biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT saramariotto biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT micheletinazzi biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses AT stefanotamburin biomarkersforcognitiveimpairmentinalphasynucleinopathiesanoverviewofsystematicreviewsandmetaanalyses |